BFM
CAI

Boothbay Fund Management’s Caris Life Sciences CAI Stock Holding History

Boothbay Fund Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,490
Closed -$445K – 2573
2025
Q4 		$445K Buy
+16,490
New +$464K 0.01% 1208
2025
Q3 		– Sell
-16,880
Closed -$451K – 2262
2025
Q2 		$451K Buy
+16,880
New +$455K 0.01% 941

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Boothbay Fund Management's CAI Position: Q1 2026 in Review

Boothbay Fund Management sold out of Caris Life Sciences (CAI) in Q1 2026, closing a stake of 16,490 shares — an estimated $445K sold.

Boothbay Fund Management first reported a position in CAI in Q2 2025 and held it in 2 quarters. The position peaked at $451K in Q2 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Boothbay Fund Management reported no remaining Caris Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 16,490 Caris Life Sciences shares in Q1 2026, an estimated $445K.
  • Boothbay Fund Management first reported a position in Caris Life Sciences in Q2 2025 and held it in 2 quarters.
  • Boothbay Fund Management's Caris Life Sciences position peaked at $451K in Q2 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.